TY - JOUR
T1 - The relative impact of vision impairment and cardiovascular disease on quality of life
T2 - The example of pseudoxanthoma elasticum
AU - Finger, Robert P.
AU - Fenwick, Eva
AU - Marella, Manjula
AU - Charbel Issa, Peter
AU - Scholl, Hendrik P.N.
AU - Holz, Frank G.
AU - Lamoureux, Ecosse L.
N1 - Funding Information:
Support: European Commission, FP7, Marie Curie Intra-European Fellowship (237238); University of Bonn BONFOR research grant and German Research Council grant (DFG FI 1540/5-1) to RPF. CERA receives Operational Infrastructure Support from the Victorian Government. RPF and EF had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
PY - 2011/12/12
Y1 - 2011/12/12
N2 - Objective: To investigate the impact of pseudoxanthoma elasticum (PXE), a rare hereditary disease of concurrent vision impairment (VI) and cardiovascular complications (CVCs), on vision-related (VRQoL) and health-related quality of life (HRQoL).Methods: VRQoL and HRQoL were assessed using the Impact of Vision Impairment (IVI) questionnaire and the Short Form Health Survey (SF-36) in 107 PXE patients. Patients were stratified into four groups: A = no VI or CVC; B = CVCs only; C = VI only; and D = both VI and CVCs.Results: Following Rasch analysis, the IVI was found to function as a vision-specific functioning and emotional well-being subscale, and the SF-36 as a health-related physical functioning and mental health subscale. The presence of VI and CVC were significant predictors of vision-specific functioning and emotional well-being (p < 0.001), with a clinically meaningful decrement in vision-specific functioning in patients with VI. No associations were found for the SF-36 Physical Functioning and Mental Health scores between any groups.Conclusions: Vision impaired patients with PXE report significantly poorer vision-specific functioning than PXE patients without VI. In contrast, the relative impact of PXE on reported general HRQoL was much less. Our results suggest that vision impairment has the larger impact on QoL in this sample.
AB - Objective: To investigate the impact of pseudoxanthoma elasticum (PXE), a rare hereditary disease of concurrent vision impairment (VI) and cardiovascular complications (CVCs), on vision-related (VRQoL) and health-related quality of life (HRQoL).Methods: VRQoL and HRQoL were assessed using the Impact of Vision Impairment (IVI) questionnaire and the Short Form Health Survey (SF-36) in 107 PXE patients. Patients were stratified into four groups: A = no VI or CVC; B = CVCs only; C = VI only; and D = both VI and CVCs.Results: Following Rasch analysis, the IVI was found to function as a vision-specific functioning and emotional well-being subscale, and the SF-36 as a health-related physical functioning and mental health subscale. The presence of VI and CVC were significant predictors of vision-specific functioning and emotional well-being (p < 0.001), with a clinically meaningful decrement in vision-specific functioning in patients with VI. No associations were found for the SF-36 Physical Functioning and Mental Health scores between any groups.Conclusions: Vision impaired patients with PXE report significantly poorer vision-specific functioning than PXE patients without VI. In contrast, the relative impact of PXE on reported general HRQoL was much less. Our results suggest that vision impairment has the larger impact on QoL in this sample.
KW - Cardiovascular disease
KW - Health-related quality of life (HRQol)
KW - Impact of vision impairment questionnaire (IVI)
KW - Pseudoxanthoma elasticum (PXE)
KW - SF-36
KW - Vision-related quality of life (VRQol)
KW - Visual impairment
UR - http://www.scopus.com/inward/record.url?scp=83155178474&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=83155178474&partnerID=8YFLogxK
U2 - 10.1186/1477-7525-9-113
DO - 10.1186/1477-7525-9-113
M3 - Article
C2 - 22152229
AN - SCOPUS:83155178474
SN - 1477-7525
VL - 9
JO - Health and Quality of Life Outcomes
JF - Health and Quality of Life Outcomes
M1 - 113
ER -